Dr. Mark A. Ware (MBBS MRCP(UK) MSc)
Since joining Canopy Growth in July 2018, Dr. Ware has helped establish the Company’s global medical division, Spectrum Therapeutics and led the team responsible for the supply and regulatory documentation, clinical development, medical affairs and global product safety.
As CMO, Dr. Ware advises on scientific and ethical aspects of Canopy Growth’s global research efforts and is responsible for the Company’s product safety program encompassing all R&D and commercial activities.
Before joining Canopy Growth, Dr. Ware was a tenured associate professor in the Faculty of Medicine at McGill University. He obtained his medical degree at the University of the West Indies, undertook training in internal medicine, and secured a Master’s degree in epidemiology. He began evaluating the role of cannabis in pain management at McGill University in 1999. He served as Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre for over ten years.
He was a co-founder of the non-profit Canadian Consortium for the Investigation of Cannabinoids and served as Executive Director from 2007 to 2018. He has advised the Canadian federal government on cannabis policy since 2001. In 2016, he served as the Federal Task Force’s vice-chair on the Legalization and Regulation of Cannabis in Canada. In 2021, Dr. Ware completed the ICD-Rotman Directors Education Program (DEP), given to business leaders committed to the highest standard of directorship while contributing to best in class governance education, thought leadership, and peer-to-peer networking.
He has over 100 publications on cannabis and pain in peer-reviewed journals and has spoken widely and national and international conferences on cannabis in medicine.Leadership Team